A Study of Oral Sapacitabine in Patients With Previously Treated Non-Small Cell Lung Cancer
Status:
Terminated
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
This is an open label, single arm, phase II study to evaluate the safety and efficacy of oral
sapacitabine administered twice daily for 5 consecutive days every week for 2 weeks followed
by 7-day rest in patients who have had one prior chemotherapy regimen for advanced Non-Small
Cell Lung Cancer (NSCLC).